$LSTA

Wall Street closed higher with the Dow Jones up 1.1% (556 points) to 52,178, while the S&P 500 and Nasdaq gained 0.3% and 0.1% respectively. Tech stocks lagged due to AI development cost concerns. CoreWeave rebounded 10% after early losses. Bank of America upgraded CarMax to 'buy' with a $65 target. Ericsson rose 9% on strong Q3 sales growth, and Taiwan Semiconductor reported a 69% net income increase.

LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Lisata Therapeutics Appoints Jeff Farrow to Board of Directors Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee Liberty Corner, N.J., October 14, 2026 - Li

Lisata Therapeutics (LSTA) appointed Jeffrey Farrow to its board, effective October 13, 2026. Farrow, currently CFO of Tarsus Pharmaceuticals (TARS), will serve on the audit committee. Lisata is a clinical-stage pharmaceutical company developing treatments for severe hypertriglyceridemia and acromegaly.

Lisata Therapeutics (LSTA) received a new US patent for its drug certepetide, covering its use with anti-cancer agents to treat pancreatic cancer and other solid tumors. The patent expires in 2041, with market exclusivity until 2043. The company claims certepetide enhances drug delivery and tumor susceptibility to immunotherapies, showing promising safety and efficacy in trials.

Marea Therapeutics, a subsidiary of Lisata Therapeutics (LSTA), dosed the first patient in a Phase 2 trial of MAR002 for acromegaly. MAR002 is a potential best-in-class therapy that may enable dosing as infrequently as once every two weeks. The trial aims to enroll 72 participants, with a primary endpoint of IGF-1 reduction after 10 weeks of treatment.

Lisata Therapeutics, Inc. raised $352 million in a securities offering. The company, incorporated in Delaware, is involved in the healthcare industry. The offering was filed with the SEC under Rule 506(b).

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and secured $225M in financing, diluting legacy shareholders to 2.39% ownership. The funds will support operations into 2028, covering clinical trials for severe hypertriglyceridemia and acromegaly. Success could attract partnerships or improve future financing terms, but risks include clinical trial failures and cash settlement obligations.

Lisata Therapeutics acquired Marea Therapeutics in a stock-for-stock deal with a $225M private placement, gaining access to Marea's cardioendocrine pipeline. Aethlon Medical merged with North Immunology in an all-stock deal with a $180M private placement, focusing on NOR-101 for atopic dermatitis. Both deals aim to advance pipelines and create value for shareholders.

Lisata Therapeutics (LSTA) acquired Marea Therapeutics and raised $225M in private financing. The deal expands Lisata's portfolio into cardioendocrine therapeutics. Proceeds will fund clinical trials for MAR001/005 and MAR002, with data expected in Q4 2027. LSTA shares rose 20.41% to $1.77. Post-transaction, former Marea equity holders will own 59.54% of Lisata.

Lisata Therapeutics (LSTA) acquired Marea Therapeutics in a stock-for-stock deal, raising $225M in private placement. Lisata shares surged 20% after the news. The acquisition focuses on advancing Marea's cardioendocrine disease treatments, with key clinical milestones expected in 2027. Investors include RA Capital, Forbion, and Third Rock Ventures.